Gastric Fundal Treatment Plus Antral Myotomy for Weight Loss in Obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial explores a combination of two endoscopic procedures, gastric fundal mucosal ablation (GFMA) and bariatric endoscopic antral myotomy (BEAM), to slow stomach emptying and reduce appetite. Eligible participants have a BMI between 30 and 40 kg/m2 (or 27–29.9 with obesity-related conditions) and no prior stomach surgeries. The approach aims to shrink the fundus and delay gastric emptying, potentially leading to meaningful weight loss with device-free recovery. Outcomes focus on weight loss, safety, and tolerability of the combined procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Body mass index (BMI) of ≥ 30 kg/m2 up to 40 kg/m2. BMI of 27.0 to 29.9 kg/m2 will be included on the condition of the presence of at least 1 obesity-related comorbidity (Indications based according to the American and European societies for bariatric endoscopy guidelines)

Exclusion Criteria:

* Subjects with any previous surgeries to the stomach
* Any previous bariatric procedures
* Any current medications for the management of obesity (must be stopped at least 3 months before recruitment)
* Evidence of severe gastritis, gastric peptic ulcer, or gastric cancer
* Coagulopathy
* Pregnancy

Where it's running

• Kar-Alaini hospital (Cairo Univeristy hospital)
  Cairo, Egypt Recruiting

Study contacts

• Study coordinator: Hany Shehab, MD, FRCP
• Email: h.shehab@kasralainy.edu.eg
• Phone: +201111111071

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How incretin treatments affect muscle mass and function in people with overweight or obesity

  This study will see how drugs like semaglutide and tirzepatide influence fat-free mass, muscle strength, and physical function in adults with overweight or obesity.

  Recruiting Radboud University Medical Center · Amsterdam and 1 other locations · NCT07929831

• Dose find for remimazolam plus alfentanil for gastroscopy in obese adults

  This trial tests what dose of remimazolam besylate with alfentanil best sedates obese adults during gastroscopy.

  Recruiting Qianfoshan Hospital · Jinan, Shandong · NCT07925684

• Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults

  This study compares how much weight adults lose over two years when starting GLP-1 medicines versus adults who had sleeve gastrectomy at the same center.

  Recruiting Yuzuncu Yil University · Van · NCT07901777

• Gut barrier and inflammation after fast-food overfeeding in adults

  This study tests whether 14 days of fast-food overfeeding can alter gut barrier function and trigger inflammation in adults who are generally healthy.

  Recruiting University Hospital, Gentofte, Copenhagen · Hellerup · NCT07893743

• High BMI and periodontitis in Thai adults under 60

  This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.

  Recruiting Mahidol University · Bangkok, Ratchathewi · NCT07880717

• GLP-1 weight‑loss medicine: finding who will benefit most

  This study tests whether a GLP-1 drug called semaglutide helps with weight loss by changing eating behavior, to see which people it helps the most.

  Recruiting Phase 4 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07870538

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.